This morning Champignon Brands (CSE: SHRM) announced they have sponsored TheraPsil, a BC-based non-profit coalition of healthcare professionals, policy-makers and community leaders seeking legal access to psilocybin for British Columbians with a palliative diagnosis and psychological distress.
The TheraPsil coalition will start in 2020 seeking legal access to psilocybin for British Columbians with a palliative diagnosis and psychological distress. The non profit is based out of Victoria, British Columbia and was established in 2019. The company tells us the focus will be aimed at:
- Compassionate Access: Establishing safe, and legal access to psychedelic-assisted therapy for those in medical need;
- Public Education: Increasing awareness of the merits and limitations of psychedelic-assisted therapy;
- Professional Training: Developing safe, simple and effective protocols for credentialed health professionals to deliver psilocybin-assisted therapy, in collaboration with other active organizations; and,
- Research: Facilitate research and evaluation in collaboration with Canadian and international partners.
Champignon Brands last traded at $1.86. However, yesterday with Canadian markets closed and US markets open, Champignon saw their common stock increase 21.97% to 1.61 USD.
FULL DISCLOSURE: Champignon Brands is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Champignon Brands on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
SmallCapSteve started blogging in the Winter of 2009. During that time, he was able to spot many take over candidates and pick a variety of stocks that generated returns in excess of 200%. Today he consults with microcap companies helping them with capital markets strategy and focuses on industries including cannabis, tech, and junior mining.
The post Champignon Sponsors Group Focused on Medical Psilocybin Access Aimed at Palliative Cancer Patients appeared first on the deep dive.